NCT03389932Completed
Explore Transplant @Home Within Kaiser Permanente Southern California
Working Within an Integrated Learning Healthcare System to Improve Living Kidney Donation Knowledge Across the CKD Continuum for All Racial Groups
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
Today, there are 25 million Americans with chronic kidney disease (CKD) and 660,000 patients in full kidney failure, the final CKD stage, known as end stage renal disease (ESRD). Over half of ESRD patients are Black, Hispanic, or Asian. ESRD patients must either receive regular dialysis treatments, by which waste is filtered from the blood by a machine, or a kidney transplant from a deceased or living donor. Five-year survival on dialysis is only 40%, compared to 74% with a deceased donor kidney transplant (DDKT) and 87% with a living donor kidney transplant (LDKT). Despite the known health benefits of DDKT and LDKT, 70% of ESRD patients remain on dialysis, especially ethnic/racial minorities. An American Society of Transplantation (AST) Consensus Conference recently recommended that patients in all CKD stages should have the opportunity to learn about and decide which treatment option is right for them, particularly about LDKT. However, early education about LDKT and DDKT is inconsistent and often poor, with early stage CKD patients and ethnic/racial minorities even less likely to receive it. Through previous HRSA grants, Dr. Waterman designed the Explore Transplant@Home (ET@Home) video-guided education program, and found that it significantly increased LDKT knowledge and informed decision-making for Black and White dialysis patients in Missouri when delivered by mail and supported through bimonthly postcards and texting. Now based at the University of California, Los Angeles (UCLA), she has partnered with Kaiser Permanente Southern California (KPSC), an integrated learning healthcare system providing insurance coverage and comprehensive care to 65,000 patients in CKD Stages 3, 4 and 5 (ESRD) (24% Hispanic, 52% White, 15% Black, and 9% Asian; 10% Spanish-speaking).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 977 (actual)
- First submitted
- 26 Dec 2017
- Start date
- 11 Jul 2018
- Primary completion date
- 31 May 2020
- Lead sponsor
- The Methodist Hospital Research Institute
- Diseases
- Chronic kidney disease
- NCT number
- NCT03389932
What you commit to
- Study type: Interventional
- Participants enrolled: 977
- From 11 Jul 2018 to the primary completion date, 31 May 2020
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Participant is not classified as having CKD 3,4, or 5.
- Participant cannot speak or read in English or Spanish.
Who the study is looking for
- Participant must be at least 18 years of age.
- Participant must self-identify as African American, White, Hispanic, or Asian.
- Participant must currently be classified as having CKD 3, 4 or 5.
- Participant must be able to speak and read in English or Spanish.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kaiser Permanente Research and Evaluation Coordinator of this site? Confirm its status | Pasadena | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.